#Victoria 2 ita trial#

A 1-year overall survival rate of 65% was achieved for both patient cohorts. Tebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and patients with metastatic cutaneous melanoma. Treatment efficacy, treatment-related adverse events, and biomarker assessments were performed for blood-derived and tumor biopsy samples obtained at baseline and on-treatment.

#Victoria 2 ita trial#

Here, we report a multicenter phase I/II trial of tebentafusp in metastatic melanoma ( NCT01211262) focusing on the mechanism of action of tebentafusp.Д®ighty-four patients with advanced melanoma received tebentafusp. Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells to kill gp100-expressing tumor cells. 11 Yale Cancer Center, Yale School of Medicine, Yale, Connecticut.10 Immunooncology, The Angeles Clinic and Research Institute, Los Angeles, California.9 Memorial Sloan Kettering Cancer Center, New York, New York.8 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.

7 Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom.6 Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.4 Cambridge University Hospitals, NHS Foundation Trust, Cambridge, United Kingdom.3 Department of Oncology, Medical Sciences Division, University of Oxford, Headington, Oxford, United Kingdom.2 Immunocore Ltd, Abingdon, Oxford, United Kingdom.

1 Department of Oncology, Medical Sciences Division, University of Oxford, Headington, Oxford, United Kingdom.